| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDC2 |
| Uniprot No | P34741 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-201aa |
| 氨基酸序列 | MRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGADEDVESPELTTSRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERKMDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYDLGERKPSSAAYQKAPTKEFYA |
| 预测分子量 | 22,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SDC2重组蛋白的参考文献示例(注：内容为模拟概括，实际文献需根据具体研究查询)：
1. **"Recombinant Syndecan-2 Protein Suppresses Tumor Angiogenesis by Blocking VEGF Signaling"**
- 作者：Kim J, et al.
- 摘要：研究通过大肠杆菌表达系统制备重组SDC2胞外域蛋白，发现其能抑制血管内皮生长因子(VEGF)与受体结合，减少肿瘤血管生成，并在小鼠模型中显著降低结肠癌生长速率。
2. **"Expression and Functional Characterization of Recombinant Human SDC2 in Chronic Inflammation"**
- 作者：Wang L, et al.
- 摘要：利用哺乳动物细胞系(HEK293)表达带有His标签的重组人SDC2蛋白，证实其通过调控TLR4/NF-κB通路减轻巨噬细胞的炎症反应，为治疗炎症性疾病提供潜在策略。
3. **"SDC2 Recombinant Protein as a Novel Biomarker for Early Colorectal Cancer Detection"**
- 作者：Chen X, et al.
- 摘要：开发基于重组SDC2蛋白的血清ELISA检测方法，发现其在结直肠癌患者血清中异常高表达，敏感性和特异性优于传统标志物，具有临床诊断潜力。
建议通过PubMed或Web of Science以关键词“recombinant SDC2/Syndecan-2”检索最新文献获取准确信息。
**Background of SDC2 Recombinant Protein**
Syndecan-2 (SDC2), a member of the syndecan family of transmembrane heparan sulfate proteoglycans (HSPGs), plays critical roles in cell-matrix adhesion, migration, and signaling. Structurally, SDC2 consists of an extracellular domain modified with heparan sulfate (HS) chains, a single transmembrane region, and a short cytoplasmic tail containing conserved motifs that mediate intracellular signaling. It interacts with extracellular matrix (ECM) components, growth factors (e.g., FGF2. VEGF), and cytokines, modulating cellular responses such as proliferation, differentiation, and cytoskeletal organization.
SDC2 is notably implicated in pathological processes, including tumor progression and metastasis. It regulates cell adhesion by forming complexes with integrins and other receptors, influencing cancer cell invasiveness. Additionally, SDC2 participates in angiogenesis, inflammation, and tissue repair, highlighting its dual role in homeostasis and disease.
Recombinant SDC2 protein is produced using genetic engineering techniques, often expressed in mammalian or bacterial systems to ensure proper post-translational modifications (e.g., HS chains) or simplified structures for specific applications. Purified recombinant SDC2 retains functional domains, enabling in vitro studies to dissect its interactions, signaling pathways, and therapeutic potential. Researchers utilize this tool to investigate SDC2's role in cancer biology, fibrosis, and regenerative medicine, as well as to screen for inhibitors or agonists targeting its activity. Its applications extend to developing diagnostic biomarkers and engineered biomaterials for tissue engineering.
In summary, SDC2 recombinant protein serves as a versatile reagent for exploring HSPG-mediated mechanisms and advancing therapeutic strategies in diverse biomedical fields.
×
